Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW, Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams
Clin Infect Dis. 2015 60 (12): 1860-3

PMID: 25722197 · PMCID: PMC4542662 · DOI:10.1093/cid/civ155

MeSH Terms (17)

Alkynes Antitubercular Agents Arylamine N-Acetyltransferase Benzoxazines Cyclopropanes Cytochrome P-450 CYP2B6 Female Genotype HIV Infections Humans Male Peru Pharmacogenetics Rifampin South Africa Tuberculosis Uganda

Connections (1)

This publication is referenced by other Labnodes entities: